Importance of tumor volume, overall treatment time and fractionation sensitivity for p16-positive and p16-negative oropharyngeal tumors

References

• Munro TR, Gilbert CW. The relation between tumour lethal doses and the radiosensitivity of tumour cells. Br J Radiol. 1961;34(400):246–251. doi: 10.1259/0007-1285-34-400-246.
   PubMed Web of Science ®Google Scholar
• Lok BH, Setton J, Caria N, et al. Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys. 2012;82(5):1851–1857. doi: 10.1016/j.ijrobp.2011.03.029.
   PubMed Web of Science ®Google Scholar
• Chao KSC, Ozyigit G, Blanco AI, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2004;59(1):43–50. doi: 10.1016/j.ijrobp.2003.08.004.
   PubMed Web of Science ®Google Scholar
• Adrian G, Carlsson H, Kjellén E, et al. Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy. Radiat Oncol. 2022;17(1):107. doi: 10.1186/s13014-022-02074-7.
   PubMed Web of Science ®Google Scholar
• Brenner DJ. Dose, volume, and tumor-control predictions in radiotherapy. Int J Radiat Oncol Biol Phys. 1993;26(1):171–179. doi: 10.1016/0360-3016(93)90189-3.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Johansen LV, Overgaard J, et al. Clinical radiobiology of squamous cell carcinoma of the oropharynx. Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 1991;20:1197–1206. doi: 10.1016/0360-3016(91)90228-v.
   Google Scholar
• McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol. 2018;64(1):01TR01. doi: 10.1088/1361-6560/aaf26a.
   PubMed Web of Science ®Google Scholar
• van Leeuwen CM, Oei AL, Crezee J, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13(1):96. doi: 10.1186/s13014-018-1040-z.
   PubMedGoogle Scholar
• Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;6736:1–11.
   Google Scholar
• Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–1626. doi: 10.1016/S0140-6736(20)30932-6.
   PubMed Web of Science ®Google Scholar
• You R, Liu YY-L, Xie Y-L, et al. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;6736:1–11.
   Google Scholar
• Horiot JC, Le Fur R, N’Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992;25(4):231–241. doi: 10.1016/0167-8140(92)90242-m.
   PubMed Web of Science ®Google Scholar
• Pinto LH, Canary PC, Araújo CM, et al. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1991;21(3):557–562. doi: 10.1016/0360-3016(91)90670-y.
   PubMed Web of Science ®Google Scholar
• Beitler JJ, Zhang Q, Fu KK, et al. Final results of local-regional control and late toxicity of rtog 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2014;89(1):13–20. doi: 10.1016/j.ijrobp.2013.12.027.
   PubMed Web of Science ®Google Scholar
• Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–1237. doi: 10.1016/S1470-2045(17)30458-8.
   PubMed Web of Science ®Google Scholar
• Withers HR, Peters LJ, Taylor JMG, et al. Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys. 1995;33(3):549–562. doi: 10.1016/0360-3016(95)00228-Q.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Thames HD. Clinical evidence for tumor clonogen regeneration: interpretations of the data. Radiother Oncol. 1991;22(3):161–166. doi: 10.1016/0167-8140(91)90019-d.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Lindstrom MJ. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23(2):457–467. doi: 10.1016/0360-3016(92)90768-d.
   PubMed Web of Science ®Google Scholar
• Skladowski K, Maciejewski B, Golen M, et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys. 2006;66(3):706–713. doi: 10.1016/j.ijrobp.2006.05.026.
   PubMed Web of Science ®Google Scholar
• Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. Radiother Oncol. 1999;52(2):137–148. doi: 10.1016/s0167-8140(99)00087-0.
   PubMed Web of Science ®Google Scholar
• Bourhis J, Lapeyre M, Tortochaux J, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol. 2006;24(18):2873–2878. doi: 10.1200/JCO.2006.08.057.
   PubMed Web of Science ®Google Scholar
• Zackrisson B, Kjellén E, Söderström K, et al. Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial. Radiother Oncol. 2015;117(1):99–105. doi: 10.1016/j.radonc.2015.09.024.
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362(9388):933–940. doi: 10.1016/s0140-6736(03)14361-9.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550–4559. doi: 10.1200/JCO.2013.50.3870.
   PubMed Web of Science ®Google Scholar
• Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35. doi: 10.1056/NEJMoa0912217.
   PubMed Web of Science ®Google Scholar
• Johnson CR, Thames HD, Huang DT, et al. The tumor volume and clonogen number relationship: tumor control predictions based upon tumor volume estimates derived from computed tomography. Int J Radiat Oncol Biol Phys. 1995;33(2):281–287. doi: 10.1016/0360-3016(95)00119-j.
   PubMed Web of Science ®Google Scholar
• Adrian G, Gebre‐Medhin M, Kjellén E, et al. Altered fractionation diminishes importance of tumor volume in oropharyngeal cancer: subgroup analysis of ARTSCAN‐trial. Head Neck. 2020;42(8):2099–2105. doi: 10.1002/hed.26142.
   PubMed Web of Science ®Google Scholar
• Strongin A, Yovino S, Taylor R, et al. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(5):1823–1830. doi: 10.1016/j.ijrobp.2010.10.053.
   PubMed Web of Science ®Google Scholar
• Panje C, Riesterer O, Glanzmann C, et al. Neutrophil-lymphocyte ratio complements volumetric staging as prognostic factor in patients treated with definitive radiotherapy for oropharyngeal cancer. BMC Cancer. 2017;17(1):643. doi: 10.1186/s12885-017-3590-0.
   PubMedGoogle Scholar
• Schüttrumpf L, Marschner S, Scheu K, et al. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group “personalized radiotherapy in head and neck cancer. Radiat Oncol. 2020;15(1):7. doi: 10.1186/s13014-019-1452-4.
   PubMed Web of Science ®Google Scholar
• Adrian G. Comment on Russo et al. Does tumor volume have a prognostic role in oropharyngeal squamous cell carcinoma? A systematic review and meta-analysis. Cancers. 2022;14(17):4283. doi: 10.3390/cancers14174283.
   PubMed Web of Science ®Google Scholar
• Davis KS, Lim CM, Clump DA, et al. Tumor volume as a predictor of survival in human papillomavirus-positive oropharyngeal cancer. Head Neck. 2016;38(Suppl 1): e1613–7. doi: 10.1002/hed.24287.
   PubMedGoogle Scholar
• Nathu RM, Mancuso AA, Zhu TC, et al. The impact of primary tumor volume on local control for oropharyngeal squamous cell carcinoma treated with radiotherapy. Head Neck. 2000;22(1):1–5. doi: 10.1002/(SICI)1097-0347(200001)22:1<1::AID-HED1>3.0.CO;2-6.
   PubMed Web of Science ®Google Scholar
• Hermans R, Op de Beeck K, Van den Bogaert W, et al. The relation of CT-determined tumor parameters and local and regional outcome of tonsillar cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2001;50(1):37–45. doi: 10.1016/s0360-3016(00)01559-5.
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Mancuso AA, Strojan P, et al. Impact of primary tumor volume on local control after definitive radiotherapy for head and neck cancer. Head Neck. 2014;36:1363–1367.
   PubMed Web of Science ®Google Scholar
• Carpén T, Saarilahti K, Haglund C, et al. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy. Strahlenther Onkol. 2018;194(8):759–770. doi: 10.1007/s00066-018-1309-z.
   PubMed Web of Science ®Google Scholar
• Kjems J, Håkansson KE, Kristensen CA, et al. The influence of tumor volume on the risk of distant metastases in head and neck squamous cell carcinomas. Radiother Oncol. 2023;186:109771. doi: 10.1016/j.radonc.2023.109771.
   PubMed Web of Science ®Google Scholar
• Huang YH, Yeh CH, Cheng NM, et al. Cystic nodal metastasis in patients with oropharyngeal squamous cell carcinoma receiving chemoradiotherapy: relationship with human papillomavirus status and failure patterns. PLOS One. 2017;12(7):e0180779. doi: 10.1371/journal.pone.0180779.
   PubMed Web of Science ®Google Scholar
• Linge A, Lohaus F, Löck S, et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: a multicentre retrospective study of the German cancer consortium radiation. Radiother Oncol. 2016;121(3):364–373. doi: 10.1016/j.radonc.2016.11.008.
   PubMed Web of Science ®Google Scholar
• Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(2):541–550. doi: 10.1158/1055-9965.EPI-08-0347.
   PubMed Web of Science ®Google Scholar
• Grønhøj C, Jensen JS, Wagner S, et al. Impact on survival of tobacco smoking for cases with oropharyngeal squamous cell carcinoma and known human papillomavirus and p16-status: a multicenter retrospective study. Oncotarget. 2019;10(45):4655–4663. doi: 10.18632/oncotarget.27079.
   PubMedGoogle Scholar
• Broughman JR, Xiong DD, Moeller BJ, et al. Rethinking the 10-pack-year rule for favorable human papillomavirus–associated oropharynx carcinoma: a multi-institution analysis. Cancer. 2020;126(12):2784–2790. doi: 10.1002/cncr.32849.
   PubMed Web of Science ®Google Scholar
• Hildingsson S, Gebre-Medhin M, Zschaeck S, et al. Hypoxia in relationship to tumor volume using hypoxia PET-imaging in head & neck cancer – A scoping review. Clin Transl Radiat Oncol. 2022;36:40–46. doi: 10.1016/j.ctro.2022.06.004
   PubMed Web of Science ®Google Scholar
• Maciejewski B, Withers HR, Taylor JMG, et al. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys. 1989;16(3):831–843. doi: 10.1016/0360-3016(89)90503-8.
   PubMed Web of Science ®Google Scholar
• Barton MB, Keane TJ, Gadalla T, et al. The effect of treatment time and treatment interruption on tumour control following radical radiotherapy of laryngeal cancer. Radiother Oncol. 1992;23(3):137–143. doi: 10.1016/0167-8140(92)90323-m.
   PubMed Web of Science ®Google Scholar
• Suwinski R, Wzietek I, Tarnawski R, et al. Moderately low alpha/beta ratio for rectal cancer may best explain the outcome of three fractionation schedules of preoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69(3):793–799. doi: 10.1016/j.ijrobp.2007.03.046.
   PubMed Web of Science ®Google Scholar
• Dische S, Saunders M, Barrett A, et al. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44(2):123–136. doi: 10.1016/s0167-8140(97)00094-7.
   PubMed Web of Science ®Google Scholar
• Hansen O, Overgaard J, Hansen HS, et al. Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. Radiother Oncol. 1997;43(1):47–51. doi: 10.1016/s0167-8140(97)01904-x.
   PubMed Web of Science ®Google Scholar
• Baumann M, Petersen C, Wolf J, et al. No evidence for a different magnitude of the time factor for continuously fractionated irradiation and protocols including gaps in two human squamous cell carcinoma in nude mice. Radiother Oncol. 2001;59(2):187–194. doi: 10.1016/s0167-8140(01)00283-3.
   PubMed Web of Science ®Google Scholar
• Lassen P, Eriksen JG, Krogdahl A, et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol. 2011;100(1):49–55. doi: 10.1016/j.radonc.2011.02.010.
   PubMed Web of Science ®Google Scholar
• Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131–146. doi: 10.3109/02841868809090333.
   PubMed Web of Science ®Google Scholar
• Dubben HH. Local control, TCD50 and dose-time prescription habits in radiotherapy of head and neck tumours. Radiother Oncol. 1994;32(3):197–200. doi: 10.1016/0167-8140(94)90018-3.
   PubMed Web of Science ®Google Scholar
• Petersen C, Zips D, Krause M, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys. 2001;51(2):483–493. doi: 10.1016/s0360-3016(01)01686-8.
   PubMed Web of Science ®Google Scholar
• Tarnawski R, Fowler J, Skladowski K, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys. 2002;54(1):229–236. doi: 10.1016/s0360-3016(02)02936-x.
   PubMed Web of Science ®Google Scholar
• Lassen P, Lacas B, Pignon JP, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project. Radiother Oncol. 2018;126(1):107–115. doi: 10.1016/j.radonc.2017.10.018.
   PubMed Web of Science ®Google Scholar
• Gorphe P, Classe M, Ammari S, et al. Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma. Radiother Oncol. 2022;168:40–45. doi: 10.1016/j.radonc.2022.01.021.
   PubMed Web of Science ®Google Scholar
• Soliman M, Yaromina A, Appold S, et al. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial. Radiother Oncol. 2013;106(3):299–304. doi: 10.1016/j.radonc.2012.12.008.
   PubMed Web of Science ®Google Scholar
• Sjövall J, Wahlberg P, Almquist H, et al. A prospective study of positron emission tomography for evaluation of neck node response 6 weeks after radiotherapy in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38 Suppl 1:E473–9. doi: 10.1002/hed.24021.
   PubMed Web of Science ®Google Scholar